Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $569.00.
Several research firms have recently weighed in on ELV. Wells Fargo & Company lowered their target price on shares of Elevance Health from $561.00 to $557.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Royal Bank of Canada raised their price objective on shares of Elevance Health from $572.00 to $574.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Barclays initiated coverage on shares of Elevance Health in a research report on Wednesday, March 6th. They issued an “overweight” rating and a $584.00 price objective for the company. StockNews.com cut shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $580.00 price objective on shares of Elevance Health in a research report on Wednesday, April 10th.
View Our Latest Stock Report on ELV
Elevance Health Price Performance
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, January 24th. The company reported $5.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.60 by $0.02. Elevance Health had a net margin of 3.49% and a return on equity of 20.47%. The company had revenue of $42.45 billion during the quarter, compared to analysts’ expectations of $42.19 billion. During the same quarter in the prior year, the company posted $5.23 EPS. The business’s revenue was up 7.0% on a year-over-year basis. Analysts anticipate that Elevance Health will post 37.03 earnings per share for the current year.
Elevance Health Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 22nd. Investors of record on Friday, March 8th were paid a dividend of $1.63 per share. This is a positive change from Elevance Health’s previous quarterly dividend of $1.48. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $6.52 annualized dividend and a yield of 1.24%. Elevance Health’s dividend payout ratio (DPR) is presently 25.90%.
Insider Buying and Selling
In related news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total transaction of $376,500.00. Following the transaction, the director now owns 9,109 shares of the company’s stock, valued at approximately $4,554,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.35% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the stock. Sanders Capital LLC lifted its position in shares of Elevance Health by 4.6% in the fourth quarter. Sanders Capital LLC now owns 4,457,986 shares of the company’s stock worth $2,102,208,000 after purchasing an additional 196,010 shares in the last quarter. Capital International Investors lifted its position in Elevance Health by 7.9% during the fourth quarter. Capital International Investors now owns 3,374,709 shares of the company’s stock worth $1,591,237,000 after purchasing an additional 248,150 shares during the period. Alliancebernstein L.P. lifted its position in Elevance Health by 13.1% during the second quarter. Alliancebernstein L.P. now owns 3,214,663 shares of the company’s stock worth $1,428,243,000 after purchasing an additional 372,937 shares during the period. Nuveen Asset Management LLC lifted its position in Elevance Health by 1.8% during the second quarter. Nuveen Asset Management LLC now owns 3,143,404 shares of the company’s stock worth $1,396,583,000 after purchasing an additional 56,204 shares during the period. Finally, Baillie Gifford & Co. lifted its holdings in shares of Elevance Health by 0.9% in the fourth quarter. Baillie Gifford & Co. now owns 3,087,904 shares of the company’s stock worth $1,456,132,000 after acquiring an additional 27,986 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.
Elevance Health Company Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Articles
- Five stocks we like better than Elevance Health
- Upcoming IPO Stock Lockup Period, Explained
- Comprehensive PepsiCo Stock Analysis
- Profitably Trade Stocks at 52-Week Highs
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Bear Market Funds to Watch This Year
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.